Company Filing History:
Years Active: 2005
Title: Victor Matassa: Innovator in Hepatitis C Research
Introduction
Victor Matassa is a prominent inventor based in Vellehi, Italy. He has made significant contributions to the field of molecular biology, particularly in the development of peptide inhibitors for the hepatitis C virus. His innovative work has the potential to impact the treatment of this viral infection.
Latest Patents
Victor Matassa holds a patent for "Peptide inhibitors of hepatitis C virus NS3 protease." This patent describes fluorinated oligopeptides, especially those containing 4,4-difluoro-2-amino butyric acid at the C terminus, which may serve as effective inhibitors of the hepatitis C virus NS3 protease. The invention includes examples of hexapeptides optimized for binding in the S1 specificity pocket of the enzyme, displaying inhibitory concentrations at the sub-micromolar level. Additionally, embodiments of tripeptides with a keto-acid group at the C-terminus are also noted as potent inhibitors of NS3 protease. Victor Matassa has 1 patent to his name.
Career Highlights
Victor Matassa is affiliated with the Istituto di Ricerche di Biologia Molecolare P. Angeletti Spa, where he conducts his research. His work focuses on the development of innovative therapeutic strategies against viral infections, particularly hepatitis C.
Collaborations
Throughout his career, Victor has collaborated with notable colleagues, including Frank Narjes and Konrad Koehler. These collaborations have contributed to the advancement of research in the field of molecular biology.
Conclusion
Victor Matassa's contributions to the development of peptide inhibitors for hepatitis C virus NS3 protease highlight his role as an innovator in the field of molecular biology. His work has the potential to lead to significant advancements in the treatment of hepatitis C.